Table 3 Further characteristics of breast cancer patients by antibiotic use after diagnosis in England and Wales

From: Antibiotic use and survival from breast cancer: A population-based cohort study in England and Wales

Characteristics

England

Wales

None

1+

1–5

6–11

12+

None

1+

1–5

6–11

12+

Deprivation

1st fifth (deprived)

1069 (13%)

2802 (14%)

1924 (13%)

532 (14%)

346 (15%)

474 (14%)

1798 (15%)

996 (14%)

397 (15%)

405 (17%)

2nd fifth

1469 (18%)

3549 (17%)

2480 (17%)

672 (17%)

397 (17%)

644 (19%)

2257 (18%)

1279 (18%)

518 (19%)

460 (20%)

3rd fifth

1664 (20%)

4153 (20%)

2901 (20%)

790 (20%)

462 (20%)

653 (19%)

2625 (21%)

1524 (21%)

576 (21%)

525 (23%)

4th fifth

1925 (23%)

4796 (23%)

3347 (23%)

908 (23%)

541 (24%)

714 (21%)

2585 (21%)

1599 (22%)

567 (21%)

419 (18%)

5th fifth (affluent)

2164 (26%)

5159 (25%)

3656 (26%)

962 (25%)

541 (24%)

878-835 (26%)

30625 (25%)

1863-85 (26%)

674-95 (25%)

517-225 (22%)

Myocardial infarction

102 (1%)

295 (1%)

176 (1%)

80 (2%)

39 (2%)

67 (2%)

156 (1%)

93 (1%)

29 (1%)

34 (1%)

Heart failure

88 (1%)

236 (1%)

159 (1%)

53 (1%)

24 (1%)

96 (3%)

206 (2%)

117 (2%)

49 (2%)

40 (2%)

PVDa

58 (1%)

176 (1%)

104 (1%)

45 (1%)

27 (1%)

58 (2%)

176 (1%)

97 (1%)

37 (1%)

42 (2%)

Stroke

221 (3%)

634 (3%)

404 (3%)

130 (3%)

100 (4%)

139 (4%)

420 (3%)

240 (3%)

95 (3%)

85 (4%)

COPDb

75 (1%)

345 (2%)

188 (1%)

76 (2%)

81 (4%)

127 (4%)

543 (4%)

275 (4%)

122 (4%)

146 (6%)

Hemiplegia

23 (0%)

66 (0%)

43 (0%)

11 (0%)

12 (1%)

24 (1%)

92 (1%)

55 (1%)

14 (1%)

23 (1%)

Dementia

60 (1%)

104 (1%)

71 (0%)

21 (1%)

12 (1%)

40 (1%)

81 (1%)

52 (1%)

18 (1%)

11 (0%)

Liver diseases

86 (1%)

226 (1%)

157 (1%)

42 (1%)

27 (1%)

27 (1%)

101 (1%)

60 (1%)

20 (1%)

21 (1%)

Peptic ulcer

127 (2%)

421 (2%)

263 (2%)

96 (2%)

62 (3%)

41 (1%)

211 (2%)

102 (1%)

48 (2%)

61 (3%)

Diabetes

529 (6%)

1462 (7%)

977 (7%)

305 (8%)

180 (8%)

381 (11%)

1405 (11%)

828 (11%)

315 (12%)

262 (11%)

Chronic kidney disease

481 (6%)

1234 (6%)

838 (6%)

274 (7%)

122 (5%)

229 (7%)

669 (5%)

402 (6%)

155 (6%)

112 (5%)

Statin (after)3

1480 (18%)

4038 (20%)

2715 (19%)

838 (22%)

485 (21%)

566 (17%)

2431 (20%)

1376 (19%)

557 (20%)

498 (21%)

Aspirin (after)3

479 (6%)

1788 (9%)

1086 (8%)

415 (11%)

287 (13%)

278 (8%)

1319 (11%)

687 (9%)

312 (11%)

320 (14%)

Metformin (after)3

351 (4%)

1004 (5%)

658 (5%)

215 (6%)

131 (6%)

137 (4%)

504 (4%)

285 (4%)

111 (4%)

108 (5%)

HRT (before)4

1654 (20%)

5217 (25%)

3294 (23%)

1102 (29%)

821 (36%)

631 (19%)

3198 (26%)

1697 (23%)

757 (28%)

744 (32%)

Smoking: Current

498 (6%)

1375 (7%)

910 (6%)

295 (8%)

170 (7%)

413 (12%)

1977 (16%)

1108 (15%)

438 (16%)

431 (18%)

Past

1710 (21%)

4819 (24%)

3395 (24%)

896 (23%)

528 (23%)

570 (17%)

2470 (20%)

1508 (21%)

534 (20%)

428 (18%)

Never

5073 (61%)

11,717 (57%)

8329 (58%)

2159 (56%)

1229 (54%)

1863 (55%)

6850 (56%)

4086 (56%)

1515 (55%)

1249 (54%)

Missing

560 (7%)

1164 (6%)

744 (5%)

234 (6%)

186 (8%)

522 (15%)

1037 (8%)

564 (8%)

250 (9%)

223 (10%)

BMI: <18.5

137 (2%)

219 (1%)

163 (1%)

36 (1%)

20 (1%)

38 (1%)

121 (1%)

78 (1%)

24 (1%)

19 (1%)

18.5–24.9

2660 (32%)

5949 (29%)

4330 (30%)

1076 (28%)

543 (24%)

917 (27%)

3414 (28%)

2120 (29%)

732 (27%)

562 (24%)

25–29.9

2299 (28%)

5855 (29%)

4067 (28%)

1138 (29%)

650 (28%)

822 (24%)

3454 (28%)

2022 (28%)

769 (28%)

663 (28%)

≥30

1636 (20%)

5014 (25%)

3326 (23%)

1016 (26%)

672 (29%)

669 (20%)

3002 (24%)

1655 (23%)

695 (25%)

652 (28%)

Missing

1559 (19%)

3422 (17%)

2422 (17%)

598 (15%)

402 (18%)

922 (27%)

2343 (19%)

1391 (19%)

517 (19%)

435 (19%)

Mean (s.d.)

27.0 (6.0)

27.7 (5.8)

27.5 (5.7)

28.0 (5.9)

28.7 (6.2)

27.2 (5.5)

27.8 (5.8)

27.5 (5.6)

28.0 (5.7)

28.6 (6.2)

  1. aPeripheral vascular disease.
  2. bChronic obstructive pulmonary disease. 3Medication use in the year after diagnosis. 4Hormone replacement therapy use before diagnosis. 5Range used to preserve disclosure control.